Geneva’s ABCDx reaches several milestones with its acute stroke diagnostics platform

ABCDx, a Geneva-based medtech company, has reached several milestones with LVOCheck, its point-of-care platform for the triage of large vessel occlusion (LVO) stroke. The company has published clinical results in a peer-reviewed journal, completed a European research project and begun transferring the technology toward manufacturing.

LVO is one of the most severe forms of ischemic stroke, accounting for a disproportionate share of stroke-related disability, mortality and healthcare costs. Mechanical thrombectomy can dramatically improve outcomes, but access to treatment is highly time-dependent. LVOCheck is a portable device designed for use in ambulances, providing an accurate identification of LVO within ten minutes to speed up access to thrombectomy.

A new article in the journal Frontiers in Neurology presents key clinical results based on 290 patients with suspected acute ischemic stroke, including 96 with confirmed LVO. The publication provides independent scientific validation of the company’s multimodal approach, which combines blood biomarkers, clinical variables and algorithmic interpretation into a single point-of-care workflow capturing complementary dimensions of LVO, from coagulation activation and cardiac stress to neurological severity. ABCDx has also secured exclusive licences to the underlying intellectual property in several territories.

To move toward manufacturing, ABCDx has initiated the technology transfer of LVOCheck to Creonate Manufacturing, a step toward an industrialized, quality-controlled and regulatory-ready product. The milestones follow the completion of the company’s Eurostars-funded project, carried out with Charité Universitätsmedizin Berlin and FZMB GmbH between 2022 and 2026, during which ABCDx redesigned its system from a dedicated fluorescence reader to a scalable smartphone-based solution and ran clinical integration with Berlin’s STEMO mobile stroke unit.